COVID Spike antibodies in neuromuscular condition: KU experience

ABSTRACT

Objective: To report on COVID spike antibody levels in patients with various neuromuscular conditions who received vaccination and assess the effect of immunosuppressive therapies on antibody levels. Background: Little is known about the immune response to COVID vaccination in immune suppressed patient. A multiple studies showed variable data regarding the effect of immunosuppression on the immune response to the vaccination. Design/Methods: We performed a retrospective chart review on patients in neuromuscular clinic who had COVID antibody testing. We collected demographic, clinical and treatment information. Descriptive statistics was performed on the data obtained. Results: We identified 82 patients to date. There were 41 male and 41 were female. The mean age of the patients enrolled was 66.27 ±13.66 and the mean duration of antibody acquisition since last date of vaccination was 152.45 days±57.09. High antibody titer>250 was seen in 44 patients (53.56%), low titer was seen in 27 patients (32.92%) and the antibody titer was not detectable in 8 patients (9.75%). 3 patients showed detected unmeasured antibody titer. Of the 44 patients with high antibody titers, 26 patients (59.1%) were on immunosuppressive medications compared to 23 of 27patients (85.19%) with low antibody titer and 7 of 8 patients without detectable antibodies (87.5%). Conclusions: Approximately half of the patients on immunosuppressive drugs did not develop adequate antibodies level against COVID-19 virus. A larger data set will be presented at the meeting as data collection is still ongoing.